💉 Obesema 1.7 mg Injection | Semaglutide | GLP-1 Therapy | Export Supplier
Obesema 1.7 mg Injection contains Semaglutide, a GLP-1 receptor agonist used in the management of Type 2 Diabetes Mellitus. It is commonly used as part of a dose-escalation protocol to achieve improved glycemic control under medical supervision.
🔹 Product Category
Specialty Medicine (Endocrinology / GLP-1 Therapy)
🔹 Composition
Semaglutide 1.7 mg
🔹 Indications
✔ Type 2 Diabetes Mellitus
✔ Glycemic Control (as prescribed)
✔ Dose escalation phase of GLP-1 therapy
🔹 Key Benefits
✔ Supports significant HbA1c reduction
✔ Helps improve blood glucose control
✔ Once-weekly dosing (as prescribed)
✔ Part of structured GLP-1 treatment plan
🔹 Dosage & Administration
✔ Subcutaneous injection
✔ Once weekly (per physician guidance)
✔ Used after initial titration stages
🔹 Packaging
✔ Pre-filled Pen / Injection Format
✔ Export-Ready Packaging Available
✔ Cold-chain handling required
✔ Bulk Supply Supported
🔹 Storage
✔ Refrigerated (2–8°C)
✔ Do not freeze
🔹 Certifications
✔ WHO-GMP Certified
✔ COA & COPP Available (as applicable)
🌍 Target Export Markets & Cities
🇺🇸 USA: New York, Chicago, Houston
🇬🇧 UK: London, Manchester
🇦🇪 UAE: Dubai, Abu Dhabi
🇸🇬 Singapore: Singapore
🇮🇳 India: Mumbai, Delhi, Bangalore
🇵🇭 Philippines: Manila
🇻🇳 Vietnam: Ho Chi Minh City, Hanoi
🇿🇦 South Africa: Johannesburg, Cape Town
🇳🇬 Nigeria: Lagos, Abuja
🇰🇪 Kenya: Nairobi
📍 Location: Nagpur, Maharashtra, India
📦 Product Catalogue Available
✔ Diabetes Care Products
✔ GLP-1 Therapies
✔ Endocrinology Medicines
✔ Specialty Pharmaceutical Products
📞 Instant Support – Call / WhatsApp Now
📲 +91 8007161282
📲 +91 9970011496
📧 Email
✉️ sales@pacificmedicines.com
